APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK-1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global NK-1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025196 pages

Choose your research edition.

Industry ResearchNK-1 Receptor Antagonists Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal NK-1 Receptor Antagonists Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal NK-1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal NK-1 Receptor Antagonists Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global NK-1 Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NK-1 Receptor Antagonists include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NK-1 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NK-1 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK-1 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NK-1 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

NK-1 Receptor Antagonists Segment by Company

Dr. Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

Glenmark

Helsinn Healthcare

Heron Therapeutics

Lupin

MSN

Mylan

Steriscience

TerSera Therapeutics

Teva

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Hansoh Pharma

Merck

Qilu Pharmaceutical

Sandoz

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK-1 Receptor Antagonists Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK-1 Receptor Antagonists Segment by Application

Chemotherapy-induced Nausea and Vomiting (CINV)

Postoperative Nausea and Vomiting (PONV)

Other

NK-1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NK-1 Receptor Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of NK-1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of NK-1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. NK-1 Receptor Antagonists Industry Trends Table 2. NK-1 Receptor Antagonists Industry Drivers Table 3. NK-1 Receptor Antagonists Industry Opportunities and Challenges Table 4. NK-1 Receptor Antagonists Industry Restraints Table 5. Global NK-1 Receptor Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global NK-1 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global NK-1 Receptor Antagonists Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers Table 9. Global NK-1 Receptor Antagonists Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global NK-1 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global NK-1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global NK-1 Receptor Antagonists Manufacturers, Product Type & Application Table 13. Global NK-1 Receptor Antagonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global NK-1 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Netupitant Table 17. Major Manufacturers of Maropitant Table 18. Major Manufacturers of Rolapitant Table 19. Major Manufacturers of Fosaprepitant Table 20. Major Manufacturers of Aprepitant Table 21. Major Manufacturers of Other Table 22. Global NK-1 Receptor Antagonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 24. Global NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 25. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 26. Global NK-1 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 27. Global NK-1 Receptor Antagonists Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (K Units) Table 29. Global NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (K Units) Table 30. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 31. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Chemotherapy-induced Nausea and Vomiting (CINV) Table 33. Major Manufacturers of Postoperative Nausea and Vomiting (PONV) Table 34. Major Manufacturers of Other Table 35. Global NK-1 Receptor Antagonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 37. Global NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 38. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 39. Global NK-1 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 40. Global NK-1 Receptor Antagonists Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (K Units) Table 42. Global NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (K Units) Table 43. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 44. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 45. Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units) Table 47. Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 48. Global NK-1 Receptor Antagonists Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global NK-1 Receptor Antagonists Sales Forecasted Market Share by Region (2027-2032) Table 50. North America NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 52. North America NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 53. Europe NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 55. Europe NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 62. Global NK-1 Receptor Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global NK-1 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 64. Global NK-1 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 65. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 66. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 67. Dr. Reddy's Laboratories Company Information Table 68. Dr. Reddy's Laboratories Business Overview Table 69. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio Table 71. Dr. Reddy's Laboratories Recent Development Table 72. Eugia Pharma Company Information Table 73. Eugia Pharma Business Overview Table 74. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eugia Pharma NK-1 Receptor Antagonists Product Portfolio Table 76. Eugia Pharma Recent Development Table 77. Fresenius Kabi Company Information Table 78. Fresenius Kabi Business Overview Table 79. Fresenius Kabi NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio Table 81. Fresenius Kabi Recent Development Table 82. Glenmark Company Information Table 83. Glenmark Business Overview Table 84. Glenmark NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Glenmark NK-1 Receptor Antagonists Product Portfolio Table 86. Glenmark Recent Development Table 87. Helsinn Healthcare Company Information Table 88. Helsinn Healthcare Business Overview Table 89. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio Table 91. Helsinn Healthcare Recent Development Table 92. Heron Therapeutics Company Information Table 93. Heron Therapeutics Business Overview Table 94. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 96. Heron Therapeutics Recent Development Table 97. Lupin Company Information Table 98. Lupin Business Overview Table 99. Lupin NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Lupin NK-1 Receptor Antagonists Product Portfolio Table 101. Lupin Recent Development Table 102. MSN Company Information Table 103. MSN Business Overview Table 104. MSN NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. MSN NK-1 Receptor Antagonists Product Portfolio Table 106. MSN Recent Development Table 107. Mylan Company Information Table 108. Mylan Business Overview Table 109. Mylan NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Mylan NK-1 Receptor Antagonists Product Portfolio Table 111. Mylan Recent Development Table 112. Steriscience Company Information Table 113. Steriscience Business Overview Table 114. Steriscience NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Steriscience NK-1 Receptor Antagonists Product Portfolio Table 116. Steriscience Recent Development Table 117. TerSera Therapeutics Company Information Table 118. TerSera Therapeutics Business Overview Table 119. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 121. TerSera Therapeutics Recent Development Table 122. Teva Company Information Table 123. Teva Business Overview Table 124. Teva NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Teva NK-1 Receptor Antagonists Product Portfolio Table 126. Teva Recent Development Table 127. Torrent Pharmaceuticals Company Information Table 128. Torrent Pharmaceuticals Business Overview Table 129. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio Table 131. Torrent Pharmaceuticals Recent Development Table 132. Beijing Sihuan Pharmaceutical Company Information Table 133. Beijing Sihuan Pharmaceutical Business Overview Table 134. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 136. Beijing Sihuan Pharmaceutical Recent Development Table 137. Hansoh Pharma Company Information Table 138. Hansoh Pharma Business Overview Table 139. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio Table 141. Hansoh Pharma Recent Development Table 142. Merck Company Information Table 143. Merck Business Overview Table 144. Merck NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Merck NK-1 Receptor Antagonists Product Portfolio Table 146. Merck Recent Development Table 147. Qilu Pharmaceutical Company Information Table 148. Qilu Pharmaceutical Business Overview Table 149. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 151. Qilu Pharmaceutical Recent Development Table 152. Sandoz Company Information Table 153. Sandoz Business Overview Table 154. Sandoz NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Sandoz NK-1 Receptor Antagonists Product Portfolio Table 156. Sandoz Recent Development Table 157. Yichang Humanwell Pharmaceutical Company Information Table 158. Yichang Humanwell Pharmaceutical Business Overview Table 159. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 161. Yichang Humanwell Pharmaceutical Recent Development Table 162. Chia Tai Tianqing Pharmaceutical Company Information Table 163. Chia Tai Tianqing Pharmaceutical Business Overview Table 164. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 166. Chia Tai Tianqing Pharmaceutical Recent Development Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. NK-1 Receptor Antagonists Distributors List Table 170. NK-1 Receptor Antagonists Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. NK-1 Receptor Antagonists Product Image Figure 2. Global NK-1 Receptor Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK-1 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global NK-1 Receptor Antagonists Sales (2021-2032) & (K Units) Figure 5. Global NK-1 Receptor Antagonists Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 NK-1 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Netupitant Image Figure 9. Maropitant Image Figure 10. Rolapitant Image Figure 11. Fosaprepitant Image Figure 12. Aprepitant Image Figure 13. Other Image Figure 14. Global NK-1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global NK-1 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 17. Global NK-1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global NK-1 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 20. Chemotherapy-induced Nausea and Vomiting (CINV) Image Figure 21. Postoperative Nausea and Vomiting (PONV) Image Figure 22. Other Image Figure 23. Global NK-1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global NK-1 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 26. Global NK-1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global NK-1 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 29. North America NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 31. U.S. NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 36. Germany NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 43. China NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 51. Brazil NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile NK-1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global NK-1 Receptor Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global NK-1 Receptor Antagonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 62. North America NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 64. Europe NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. NK-1 Receptor Antagonists Value Chain Figure 70. Manufacturing Cost Structure Figure 71. NK-1 Receptor Antagonists Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Chemotherapy-induced Nausea and Vomiting (CINV)
  • Postoperative Nausea and Vomiting (PONV)
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Lupin
  • MSN
  • Mylan
  • Steriscience
  • TerSera Therapeutics
  • Teva
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Hansoh Pharma
  • Merck
  • Qilu Pharmaceutical
  • Sandoz
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NK-1 Receptor Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NK-1 Receptor Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global NK-1 Receptor Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global NK-1 Receptor Antagonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global NK-1 Receptor Antagonists Market Dynamics
  1. 2.1 NK-1 Receptor Antagonists Industry Trends
  2. 2.2 NK-1 Receptor Antagonists Industry Drivers
  3. 2.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK-1 Receptor Antagonists Industry Restraints
3 NK-1 Receptor Antagonists Market by Manufacturers
  1. 3.1 Global NK-1 Receptor Antagonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global NK-1 Receptor Antagonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global NK-1 Receptor Antagonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global NK-1 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NK-1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global NK-1 Receptor Antagonists Manufacturers, Product Type & Application
  7. 3.7 Global NK-1 Receptor Antagonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NK-1 Receptor Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NK-1 Receptor Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NK-1 Receptor Antagonists Tier 1, Tier 2, and Tier 3
4 NK-1 Receptor Antagonists Market by Type
  1. 4.1 NK-1 Receptor Antagonists Type Introduction
  2. 4.1.1 Netupitant
  3. 4.1.2 Maropitant
  4. 4.1.3 Rolapitant
  5. 4.1.4 Fosaprepitant
  6. 4.1.5 Aprepitant
  7. 4.1.6 Other
  8. 4.2 Global NK-1 Receptor Antagonists Sales by Type
  9. 4.2.1 Global NK-1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global NK-1 Receptor Antagonists Sales by Type (2021-2032)
  11. 4.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032)
  12. 4.3 Global NK-1 Receptor Antagonists Revenue by Type
  13. 4.3.1 Global NK-1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  15. 4.3.3 Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032)
5 NK-1 Receptor Antagonists Market by Application
  1. 5.1 NK-1 Receptor Antagonists Application Introduction
  2. 5.1.1 Chemotherapy-induced Nausea and Vomiting (CINV)
  3. 5.1.2 Postoperative Nausea and Vomiting (PONV)
  4. 5.1.3 Other
  5. 5.2 Global NK-1 Receptor Antagonists Sales by Application
  6. 5.2.1 Global NK-1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 5.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032)
  9. 5.3 Global NK-1 Receptor Antagonists Revenue by Application
  10. 5.3.1 Global NK-1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  12. 5.3.3 Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032)
6 Global NK-1 Receptor Antagonists Sales by Region
  1. 6.1 Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK-1 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global NK-1 Receptor Antagonists Sales by Region (2021-2026)
  4. 6.2.2 Global NK-1 Receptor Antagonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America NK-1 Receptor Antagonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe NK-1 Receptor Antagonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific NK-1 Receptor Antagonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa NK-1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global NK-1 Receptor Antagonists Revenue by Region
  1. 7.1 Global NK-1 Receptor Antagonists Revenue by Region
  2. 7.1.1 Global NK-1 Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global NK-1 Receptor Antagonists Revenue by Region (2021-2026)
  4. 7.1.3 Global NK-1 Receptor Antagonists Revenue by Region (2027-2032)
  5. 7.1.4 Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America NK-1 Receptor Antagonists Revenue (2021-2032)
  8. 7.2.2 North America NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe NK-1 Receptor Antagonists Revenue (2021-2032)
  11. 7.3.2 Europe NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific NK-1 Receptor Antagonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa NK-1 Receptor Antagonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa NK-1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Dr. Reddy's Laboratories
  2. 8.1.1 Dr. Reddy's Laboratories Company Information
  3. 8.1.2 Dr. Reddy's Laboratories Business Overview
  4. 8.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
  6. 8.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 8.2 Eugia Pharma
  8. 8.2.1 Eugia Pharma Company Information
  9. 8.2.2 Eugia Pharma Business Overview
  10. 8.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
  12. 8.2.5 Eugia Pharma Recent Developments
  13. 8.3 Fresenius Kabi
  14. 8.3.1 Fresenius Kabi Company Information
  15. 8.3.2 Fresenius Kabi Business Overview
  16. 8.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
  18. 8.3.5 Fresenius Kabi Recent Developments
  19. 8.4 Glenmark
  20. 8.4.1 Glenmark Company Information
  21. 8.4.2 Glenmark Business Overview
  22. 8.4.3 Glenmark NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
  24. 8.4.5 Glenmark Recent Developments
  25. 8.5 Helsinn Healthcare
  26. 8.5.1 Helsinn Healthcare Company Information
  27. 8.5.2 Helsinn Healthcare Business Overview
  28. 8.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
  30. 8.5.5 Helsinn Healthcare Recent Developments
  31. 8.6 Heron Therapeutics
  32. 8.6.1 Heron Therapeutics Company Information
  33. 8.6.2 Heron Therapeutics Business Overview
  34. 8.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
  36. 8.6.5 Heron Therapeutics Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 MSN
  44. 8.8.1 MSN Company Information
  45. 8.8.2 MSN Business Overview
  46. 8.8.3 MSN NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
  48. 8.8.5 MSN Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Steriscience
  56. 8.10.1 Steriscience Company Information
  57. 8.10.2 Steriscience Business Overview
  58. 8.10.3 Steriscience NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
  60. 8.10.5 Steriscience Recent Developments
  61. 8.11 TerSera Therapeutics
  62. 8.11.1 TerSera Therapeutics Company Information
  63. 8.11.2 TerSera Therapeutics Business Overview
  64. 8.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
  66. 8.11.5 TerSera Therapeutics Recent Developments
  67. 8.12 Teva
  68. 8.12.1 Teva Company Information
  69. 8.12.2 Teva Business Overview
  70. 8.12.3 Teva NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
  72. 8.12.5 Teva Recent Developments
  73. 8.13 Torrent Pharmaceuticals
  74. 8.13.1 Torrent Pharmaceuticals Company Information
  75. 8.13.2 Torrent Pharmaceuticals Business Overview
  76. 8.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
  78. 8.13.5 Torrent Pharmaceuticals Recent Developments
  79. 8.14 Beijing Sihuan Pharmaceutical
  80. 8.14.1 Beijing Sihuan Pharmaceutical Company Information
  81. 8.14.2 Beijing Sihuan Pharmaceutical Business Overview
  82. 8.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  84. 8.14.5 Beijing Sihuan Pharmaceutical Recent Developments
  85. 8.15 Hansoh Pharma
  86. 8.15.1 Hansoh Pharma Company Information
  87. 8.15.2 Hansoh Pharma Business Overview
  88. 8.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
  90. 8.15.5 Hansoh Pharma Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Qilu Pharmaceutical
  98. 8.17.1 Qilu Pharmaceutical Company Information
  99. 8.17.2 Qilu Pharmaceutical Business Overview
  100. 8.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  102. 8.17.5 Qilu Pharmaceutical Recent Developments
  103. 8.18 Sandoz
  104. 8.18.1 Sandoz Company Information
  105. 8.18.2 Sandoz Business Overview
  106. 8.18.3 Sandoz NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
  108. 8.18.5 Sandoz Recent Developments
  109. 8.19 Yichang Humanwell Pharmaceutical
  110. 8.19.1 Yichang Humanwell Pharmaceutical Company Information
  111. 8.19.2 Yichang Humanwell Pharmaceutical Business Overview
  112. 8.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  114. 8.19.5 Yichang Humanwell Pharmaceutical Recent Developments
  115. 8.20 Chia Tai Tianqing Pharmaceutical
  116. 8.20.1 Chia Tai Tianqing Pharmaceutical Company Information
  117. 8.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
  118. 8.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  120. 8.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NK-1 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 NK-1 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NK-1 Receptor Antagonists Production Mode & Process
  6. 9.2 NK-1 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NK-1 Receptor Antagonists Distributors
  9. 9.2.3 NK-1 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst